Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ).

Full DD Report for ARLZ

You must become a subscriber to view this report.


Recent News from (NASDAQ: ARLZ)

Aralez Pharmaceuticals: Change In Strategy May Bring A Silver Lining
Less than 2 months ago, Aralez Pharmaceuticals (Nasdaq: ARLZ ) announced its Q4 2017 and full year 2017 results, and gave optimistic financial guidance for 2018 of revenues of $140 million to $160 million and projected Adjusted EBITDA of between $35 million and $55 million. At the time thin...
Source: SeekingAlpha
Date: May, 11 2018 12:06
Today's Research Reports on Stocks to Watch: Amedica Corporation and Aralez Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 9, 2018 / Aralez Pharmaceutical shares sunk on Tuesday after reporting first quarter results, despite a third consecutive quarter of positive adjusted EBITDA. Shares of Amedica had a better day yesterday exploding to a close of over 180% after providing Wall S...
Source: ACCESSWIRE IA
Date: May, 09 2018 08:20
Midday Gainers / Losers (05/08/2018)
Gainers:  AMDA +105% . PRPH +36% . PI +29% . EGY +26% . UUU +22% . CRCM +18% . SEII +17% . NSU +17% . CDLX +15% . TCMD +16% . More news on: Amedica Corporation, ProPhase Labs, Inc., Impinj, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 08 2018 12:49
Aralez Pharmaceuticals' (ARLZ) CEO Adrian Adams on Q1 2018 Results - Earnings Call Transcript
Aralez Pharmaceuticals Inc. (ARLZ) Q1 2018 Results Earnings Conference Call May 08, 2018, 08:00 AM ET Executives Adrian Adams - CEO Nichol Ochsner - Executive Director of Investor Relations and Corporate Communications Michael Kaseta - CFO Analysts David Bautz - Zacks Equit...
Source: SeekingAlpha
Date: May, 08 2018 12:18
Premarket Losers as of 9:05 am (5/8/2018)
ARLZ   -26%  on terminating U.S. operations. More news on: Aralez Pharmaceuticals Inc., Nevro, Nobilis Health Corp., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 08 2018 09:19
Aralez revenues up 47% in Q1
Aralez Pharmaceuticals ( ARLZ ) Q1 results : Revenues: $38.1M (+46.5%); Product revenues: $34M; Other revenues: $4.1M (-78.8%). More news on: Aralez Pharmaceuticals Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 08 2018 09:01
Aralez Pharmaceuticals Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Aralez Pharmaceuticals Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 08 2018 08:12
Aralez Pharmaceuticals to wind down U.S. operations; shares off 22% premarket
Citing the Yosprala flop and insufficient momentum from Zontivity to sustain its U.S. infrastructure, Aralez Pharmaceuticals (NASDAQ: ARLZ ) has decided to terminate its U.S. operations. The move should save $25M in annual expenses. More news on: Aralez Pharmaceuticals Inc., Healthcare sto...
Source: SeekingAlpha
Date: May, 08 2018 07:55
Aralez Pharmaceuticals misses by $0.04, beats on revenue
Aralez Pharmaceuticals (NASDAQ: ARLZ ): Q1 EPS of -$0.29 misses by $0.04 . More news on: Aralez Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 08 2018 07:00
Aralez Announces First Quarter 2018 Financial Results
Aralez Announces First Quarter 2018 Financial Results Canada NewsWire MISSISSAUGA, Ontario, May 8, 2018 -1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017- MISSISSAUGA, Ontario , May 8, 2018 /CNW/ --  Aralez Pharmaceuticals Inc. ...
Source: Canada Newswire
Date: May, 08 2018 06:57

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.04930.04520.05040.04194,282,313
2018-08-160.04710.04710.05010.04014,263,460
2018-08-150.06190.04750.06460.0455,717,738
2018-08-140.0750.06390.07720.067,805,746
2018-08-130.05960.06690.0850.055520,250,873

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17403,3681,790,47122.5286Cover
2018-08-16330,3201,524,13521.6726Cover
2018-08-15407,2691,706,05923.8719Cover
2018-08-14711,1232,653,88726.7955Cover
2018-08-131,600,1835,789,98627.6371Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARLZ.


About Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ)

Logo for Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ)

Not available

 

Contact Information

 

 

Current Management

  • John R. Plachetka / CEO
  • Matthew E. Czajkowski / CFO

Current Share Structure

  • Market Cap: $33,170,389 - 05/14/2018
  • Issue and Outstanding: 67,010,887 - 03/08/2018

 


Recent Filings from (NASDAQ: ARLZ)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 30 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ARLZ)

Daily Technical Chart for (NASDAQ: ARLZ)


Stay tuned for daily updates and more on (NASDAQ: ARLZ)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ARLZ)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARLZ is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ARLZ and does not buy, sell, or trade any shares of ARLZ. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/